Slight improvement in response with temozolamide plus radiotherapy vs radiotherapy alone for STS
JPMA 70: 572. 2020 Apr 1;1:3-1.Sixty-four patients with soft tissue sarcomas (STS) were randomized to receive radiation therapy only or radiation therapy plus oral temozolomide. The primary outcome of interest was treatment response as measured by the Response Evaluation Criteria in Solid Tumours (RECIST) criteria. Secondary outcomes of interest included the incidence of adverse events. Results revealed a significantly higher incidence of rash in the combination group compared to the radiation only group. Whilst no significant differences were observed in all remaining outcomes, the number of patients with a positive treatment response was higher in the combination group, and the number of patients with cancer progression was lower in the combination group, compared to the radiation only group.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
